Placebo Response Mitigation Strategies & Tools for Optimizing Clinical Trials

Dr. Veeraindar Goli, MD, MBA, DLFAPA, Vice President, Medical and Scientific Management, Clinical Solutions, Syneos Health

Dr. Veeraindar Goli has 38 years of experience as a physician in a variety of healthcare environments. Global experience as a physician in Asia, Africa and the United States. He is triple boarded in psychiatry, addiction medicine and pain medicine and is board eligible in geriatric psychiatry. He has well-rounded and deep-rooted experience in small and large pharmaceutical companies, academia, clinical practice and clinical research organizations (CRO). He has an MBA from the prestigious Fuqua School of Business with a special focus on health sector management (HSM) and obtained both degrees from Duke University, Durham, NC. Has a current academic appointment as an Emeritus Professor at Duke University Medical Center where he worked for over 24 years as a Professor in Psychiatry and Assistant Professor in Anesthesiology. In addition, he possesses extensive experience in clinical and developmental aspects of pain medicine and maintains an active medical license in the state of Virginia and North Carolina in the USA.

Dr. Goli has direct experience as a medicine’s development lead, medical monitor, clinician and a principal investigator in all phases of clinical trials. He contributed to IND, NDA submissions, study reports and publications. Dr. Goli made significant contributions to strategic decisions, transition criteria agreements and contributions leading to the approval of NCE’s and reformulations. He had direct experience with the US Food and Drug Administration’s advisory board meeting preparations, PSP’s and clinical holds and launch of approved products. Has been with Syneos Health since 2021.

Dr. Luke Koschalka, PsyD, Sr. Clinical Scientist, Clinical Surveillance & Training (CST), Syneos Health

Dr. Luke Koschalka is a UK-trained clinical psychologist and neuropsychologist. His nearly 15 years in clinical practice saw him work initially with patients with severe and enduring psychiatric diagnoses, both in inpatient and outpatient settings, as well as addiction services. Subsequently, he worked in leadership roles in dementia diagnosis, stroke rehabilitation, acquired brain injury and other areas before moving to Imperial College London, where he led neuropsychological data collection on several large studies. In 2016, he moved to Syneos Health´s Clinical Surveillance & Training team, where he has provided scientific oversight on more than 30 Phase II and III studies, as well as acting more widely as a scientific consultant on study and protocol design.

Dr. Dominique Demolle, PhD, CEO, Cognivia

Dr. Dominique Demolle serves as Chief Executive Officer of Cognivia (formerly Tools4Patient) since its inception in 2013. Dr. Demolle holds a PhD in biochemistry from the University of Brussels. She joined the Clinical Research Group of GD Searle and then Eli Lilly. She has held positions with increasing leadership responsibilities at Eli Lilly and Company with the Lilly Indianapolis Clinical Research Unit in the US and the European Operational Staff management and ultimately became the Associate Director of Global Early Phase Operations. In 2007, she co-founded and successfully developed a consulting clinical research organization including partnerships with pharma and biotech before she left to set up Cognivia with previous colleagues. She has contributed to the clinical development of dozens of drugs and several launches.